Medical management of metastatic bone disease.
OBJECTIVE
To highlight recent advances in the medical management of metastatic bone disease.


RESULTS
Progress has been made in quality of life assessment and pain measurement; in novel ways to use bisphosphonates, especially in the adjuvant setting for prevention of bone metastases and in combination with other pharmaceutical agents, where synergistic enhancement holds high potential; in targeted therapies using novel agents, especially with denosumab which is approaching registration; in the use of bone biomarkers to direct therapy and as surrogate endpoints; in development of radiopharmaceuticals for improved treatment of disseminated bone pain.


CONCLUSIONS
Metastatic bone disease continues to present management challenges, but these challenges are being met with an increased armamentarium of available interventions.
Vasudev
Naveen S
NS
Cancer Research UK Clinical Centre at Leeds, University of Leeds, St James's Hospital, Leeds, UK.
Brown
Janet E
JE
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000523:psychology / Q000601:surgery; D000069448:Denosumab; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000517:prevention & control; D010146:Pain / Q000188:drug therapy* / Q000523:psychology; D011788:Quality of Life / Q000523:psychology; D053245:RANK Ligand / Q000627:therapeutic use; D040242:Risk Reduction Behavior
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D053245:RANK Ligand; D000069448:Denosumab